Less robust changes—not passing multiple testing correction—were observed for CRP in MCI against SCD, for FABP-3 in AD vs. SCD, for neurogranin in A+N− against A+N+, and for C3b and MIF in the stratified AD spectrum setting (Additional file 1: Tables S2 to S5). Here, NRGN is linked to Alzheimer disease.